



Corrections and clarifications in the BNF

Date posted	Edition	Versions affected	Clarification or correction		Comment
			Location	Detail	
21 April 2008	55	Book & digital	Page 487, column 1 Section 8.3.4.2	The indication and dose for bicalutamide 50mg tablets has been omitted in error. The indication should read:	The error will be corrected for the print edition of BNF 56 (September 2008) Online versions of BNF 55 (March 2008) have been corrected. An update to correct this error will be available for other digital versions of BNF 55
				Advanced prostate cancer in combination with gonadorelin analogue or surgical castration	
				The dose should read:	
				<ul style="list-style-type: none"> Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration, 50mg once daily (started at the same time as surgical castration or at least 3 days before gonadorelin therapy, see also section 8.3.4.2, p. 486, BNF 55) 	

21 April 2008	55	Book	Page xiii, column 2 Late additions	The title of the new vaccine Ambirix [®] has been incorrectly spelt as Ambrix. The index shows the same incorrect proprietary title.	Online versions of BNF 55 have been corrected. An update to correct this error will be available for other digital versions of BNF 55. The correct preparation title will be included in section 14.4 for BNF 56.
2 November 2007	54	Book & digital	Page 165, column 1 Section 3.4.1	The strength of <i>Xyzal</i> [®] oral solution is incorrect. The preparation should read as follows:	The error will be corrected for BNF 55 (March 2008)
				Oral solution ▼ , levocetirizine hydrochloride 2.5mg/5mL, net price 200 mL = £6.00. Counselling, driving	
17 October 2007	54	Book & digital	Page 469, column 2 Section 8.2.2	The dose of intravenous ciclosporin for the treatment of refractory ulcerative colitis in children is incorrect. The dose by intravenous infusion should read:	This error does not affect the adult dose The error will be corrected for the print edition of BNF 55 (March 2008)
				CHILD 3–18 years initially 0.5–1 mg/kg twice daily; dose adjusted according to blood-ciclosporin concentration and response	Online versions of BNF 54 (September 2007) have been corrected. An update to correct this error will be available for other digital versions of BNF 54
27 November 2006	52	Book & digital	Page 868, column 2	BNF 52 shows an incorrect email address for IVAX Pharmaceuticals.	Queries to IVAX should instead be made by post, telephone, or fax

8 November 2006	52	Book & digital	page 499, column 2 Section 9.5.2.1	<p>The dose of phosphate in critically ill patients shown in the notes on phosphate supplements is incorrect in BNF52. The dose should read as follows:</p> <p>In critically ill patients, the dose of phosphate can be increased up to 500 micromol/kg (approx. 30 mmol in adults), infused over 6–12 hours, according to severity.</p>	The error will be corrected for BNF53 (March 2007)
31 October 2006	52	Book & digital	page 622, column 2 section 14.4	<p>The strength of one of the Tuberculin Purified Protein Derivative preparations is incorrect. The preparation entry should read:</p> <p>Injection, heat-treated products of growth and lysis of appropriate <i>Mycobacterium</i> spp. 20 units/mL (2 units/0.1-mL dose) (for routine use), 1.5-mL vial; 100 units/mL (10 units/0.1-mL dose), 1.5-mL vial</p>	The error will be corrected for BNF 53

31 March 2006	51	Book	page 704, column 1	<p>BNF 51 (Appendix 1) should contain the following interactions for mitotane:</p> <p>Mitotane</p> <ul style="list-style-type: none"> •Anticoagulants: mitotane possibly reduces anticoagulant effect of •coumarins Antiepileptics: cytotoxics possibly reduce absorption of phenytoin •Antipsychotics: avoid concomitant use of cytotoxics with •clozapine (increased risk of agranulocytosis) Diuretics: manufacturer of mitotane advises avoid concomitant use of spironolactone (antagonism of effect) 	The error has been corrected for the digital versions of BNF 51. BNF 52 and <i>BNF for Children 2006</i> will show the interactions.
21 November 2005	50	Book & digital	page 439, column 1 section 8.1.5	<p>The pharmacology of bortezomib is incorrectly described in BNF 50. The notes on bortezomib should read:</p> <p>Bortezomib is a proteasome inhibitor,</p>	The error will be corrected in BNF 51 (March 2006).
November 2005	50	Book	Index, pages 832–866	A number of entries that should be indexed to General Guidance (pages 1–4) refer instead to an incorrect page number.	Only the book shows incorrect index entries; digital products are not affected.

19 January 2005	48	Book & digital	page 427, column 2	<p>The side-heading above <i>DaunoXome</i>[®] is incorrect. <i>DaunoXome</i>[®] is for intravenous use, as described by the product entry and in the notes above. It is not for intrathecal use. The side-heading should read as follows:</p> <p>Lipid formulation</p>	The error will be corrected in BNF 49 (March 2005). The BNF is grateful to pharmacists from James Paget Hospital who pointed out the mistake in the side-heading.
17 August 2004	47	Book & digital	page 313, column 1	<p>BNF 47 shows an incorrect dose of clindamycin for the treatment of falciparum malaria in children. The dose should read as follows:</p> <p>clindamycin 20–40 mg/kg daily in 3 divided doses for 5 days [unlicensed indication]</p>	Paediatric doses shown in the clindamycin monograph (section 5.1.6, p.276) are not affected. The error will be corrected for BNF 48 which is due to be published next month.